Drug Profile

Iodixanol - GE Healthcare

Alternative Names: DU 6807; Visipaque

Latest Information Update: 16 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GE Healthcare
Developer Daiichi Sankyo Company; GE Healthcare
Class Contrast media; Triiodobenzoic acids
Mechanism of Action Radiography enhancers; Tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Cardiovascular disorders

Most Recent Events

04 Jun 2025 Fresenius Kabi receives NOC approval from the Health Canada for Iodixanol
11 Aug 2023 First Generic equivalent available in USA used in magnetic resonance imaging (MRI) procedures
25 Jun 2019 Daiichi Sankyo agrees to return marketing rights for iodixanol to GE Healthcare in Japan

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com